March 23, 2020 / 10:19 PM / 14 days ago

BRIEF-Diamedica Therapeutics Says Remedy Phase II Study Of Dm199 Completes Enrollment

March 23 (Reuters) - DiaMedica Therapeutics Inc:

* DIAMEDICA THERAPEUTICS - REMEDY PHASE II STUDY OF DM199 IN ACUTE ISCHEMIC STROKE COMPLETES ENROLLMENT; DATA READOUT EXPECTED IN Q2 2020

* DIAMEDICA THERAPEUTICS - PHASE II STUDY OF DM199 IN CHRONIC KIDNEY DISEASE ONGOING; STEPS BEING TAKEN TO MITIGATE POTENTIAL IMPACT OF COVID-19

* DIAMEDICA THERAPEUTICS - DOES NOT CURRENTLY ANTICIPATE ANY TREATMENT DISRUPTIONS TO PATIENTS ALREADY ENROLLED IN THE REDUX STUDY FROM COVID-19

* DIAMEDICA THERAPEUTICS - CASH, INVESTMENTS OF $7.9 MILLION, $15.6 MILLION PRO FORMA WITH NET PROCEEDS FROM FEBRUARY 2020 PUBLIC OFFERING; RUNWAY THROUGH 2021 Source : (bit.ly/2WK37kR) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below